Recently, anti-programmed death receptor 1 (PD-1) or programmed death ligand 1 (PD-L1) monotherapy is considered standard therapy for unresectable, recurrent, or metastatic MCC, but primary resistance to immune checkpoint (IC) inhibitors remains a challenge. The gene discussed is CD274; the disease is Merkel cell skin cancer.